Chongqing Lummy Pharmaceutical Co., Ltd. Class A

Chongqing Lummy Pharmaceutical Co., Ltd. Class A

SSZSE:300006
9.47
CNY
-1.38
(-12.72%)
-0.11EPS
5.87BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.11
1.36
1.4
1.28
1.57
1.92
2.29
1.95
1.23
0.84
0.85
0.75
0.73
0.68
Basic EPS, GAAP
0.09
0.01
0.03
0.01
0.07
0.12
-0.19
-0.4
-0.1
-0.07
-0.01
-0.08
-0.13
-0.11
Free Cash Flow per Basic Share
-0.41
-0.3
-0.12
0.06
0.05
0.12
0.21
0.22
0.07
-0.01
0.02
0.1
-0.01
- -
Dividend per Share
0.08
0.1
0.1
0.07
0.09
0.12
0.13
0.14
0.03
0.02
0.01
0.01
0.01
0.01
Book Value per Share
1.51
1.37
2.26
2
2.08
2.08
1.92
1.44
2.04
2.01
1.97
1.78
1.66
1.63
Tangible Book Value per Share
0.93
0.74
1.59
1.38
1.47
1.44
1.41
1.11
1.85
1.75
1.74
1.53
1.45
1.41
Basic Weighted Avg Shares
684
668
687
776
817
812
812
812
995
1,055
1,050
1,055
1,056
1,056
Sales/Revenue/Turnover
759
912
964
990
1,282
1,562
1,859
1,584
1,225
885
896
796
776
720
Operating Margin (%)
11.04
6.05
10.11
9.4
7.52
10.38
4.67
-1.57
-3.84
-6.28
-5.04
-7.63
-7.66
-5.58
Depreciation Expense
51
80
105
109
107
107
109
109
75
76
73
56
53
- -
Net Income, GAAP
61
9
21
7
56
98
-155
-327
-101
-69
-9
-88
-135
-119
Effective Tax Rate (%)
15.84
- -
18.11
68.79
3.81
16.62
- -
- -
- -
- -
378.71
- -
- -
- -
Profit Margin (%)
8.01
1.02
2.14
0.71
4.33
6.27
-8.35
-20.64
-8.2
-7.77
-1
-11.04
-17.37
-16.59
Working Capital
-93
-324
348
273
249
78
48
-7
1,060
1,044
1,084
968
793
848
LT Debt
14
112
179
143
45
48
80
66
9
156
129
145
59
112
Total Equity
1,126
1,017
1,690
1,674
1,723
1,716
1,654
1,232
2,212
2,185
2,122
1,883
1,764
1,739
Return on Invested Capital (%)
3.05
- -
0.61
-0.08
2.07
3.72
- -
- -
- -
- -
-6.37
- -
- -
- -
Return on Capital (%)
6.25
- -
2.87
0.92
4.48
6.28
- -
- -
- -
- -
-1.72
- -
- -
- -
Return on Common Equity (%)
6.92
0.89
1.56
0.43
3.35
5.79
-9.56
-23.96
-6.04
-3.21
-0.42
-4.44
-7.42
-6.68

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
348
387
228
LT Borrowings
48
106
112
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,056
1,056
1,056
Market Capitalization
5,280
5,417
5,871

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,570
1,692
1,477
Cash, Cash Equivalents & STI
920
1,085
903
Accounts Receivable, Net
234
196
201
Inventories
151
178
167
Total Current Liabilities
781
852
629
Payables & Accruals
- -
- -
- -
ST Debt
348
387
228
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.04%
11.59%
-6.33%
Free Cash Flow
-14.95%
-39.27%
-111.06%
Net Income, GAAP
130.74%
149.81%
53.42%
Sales/Revenue/Turnover
-0.46%
-12.57%
-2.5%
Total Cash Common Dividend
-8.38%
-28.07%
14.7%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
181
201
224
190
796
2025
198
179
- -
195
776
2026
182
168
175
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
-0.03
-0.06
-0.08
2025
-0.01
-0.02
- -
-0.08
-0.13
2026
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

CEO
Rong Zhao Qiu
Full Time Employees
1,115
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building B, Huangshan Avenue Chongqing CH China 401121
IPO Date
Sep 24, 2009
Business
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research, development, production and sales of pharmaceutical products primarily in China. The company offers chemical drugs covering specialty categories including anti-tumor drugs, digestive drugs and parenteral nutritional drugs; anti-infective drugs; nanocarbon suspension injections (cannalin); esomeprazole sodium for injections; cefopoxime dry suspensions; esomeprazole magnesium enteric capsules; voriconazole active pharmaceutical ingredient; clindamycin hydrochloride injections; fludarabine phosphate for injections; ammonium succinate for injections; sodium methylprednisolone hydrochloride injections; as well as anti-inflammatory, antibacterial, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal and opioid receptor antagonists. It operates mainly in the domestic Chinese market with a focus on hospitals and pharmaceutical distributors; founded in 1999 and headquartered in Chongqing, China. In recent developments, a holding subsidiary of its indirect controlling shareholder Guangxi Wuzhou Zhongheng Group obtains regulatory approval from the National Medical Products Administration for supplemental applications of clindamycin phosphate injection in two specifications; the company receives registration certificates for products such as azithromycin granules and passes consistency evaluations for antibiotics; its influenza drug passes hospital ethical review; and it discloses a potential change in indirect controlling shareholder as Guangxi Investment Group Financial Holding increases its stake in the parent entity, alongside participation in industry buyout funds and partnerships for strategic investments in the pharmaceutical sector.